ABOUT THE ROLE OF THE PODOCIN PROTEIN IN DYSFUNCTION OF KIDNEYS IN PATIENTS WITH DIABETES MELLITUS TYPE 2
https://doi.org/10.24884/1561-6274-2018-22-5-31-38
Abstract
THE AIM: to investigate the role of the podocin in the progression of renal dysfunction in diabetic nephropathy (DN) in patients with diabetes mellitus (DM) type 2.
PATIENTS AND METHODS. The study was open, controlled with parallel design in patients with DM type 2 and with CKD 1-3a. The duration was 4 years. Standard methods for the assessing of hormonal and metabolic profile of the blood and functional activity of kidneys were performed in patients groups and control group. The primary endpoint is the dynamics of podocinuria in patients on the basis of the ELISA.
RESULTS: The study included 119 patients (61 men and 58 women) with Diabetes mellitus type 2. Diabetic nephropathy. CKD 1-3a. Patients were divided into 3 groups: group 1 – 37 patients with CKD Stage 1; group 2 – 47 patients with CKD Stage 2; group 3 – 35 patients with CKD Stage 3a. Control group – persons without DM and kidney injury (n=30). The participation of podocin in renal functional activity regulation (dynamics of mean values and correlations with albumin excretion rate and GFR) and hormonal and metabolic interactions (dynamics of mean values of fasting glycemia, OGTT, Hb1Ac, C-peptide, creatinine, potassium, total cholesterol, LDL-C, atherogenic index and their correlations with podocinuria) was shown in patients with DM type 2 and DN.
CONCLUSION: podocinuria interrelations with the indices of kidneys functional activity, hormonal and metabolic profile of the blood helps to detail the molecular mechanism of development of ND in type 2 diabetes. Podocin is promising biomarker of CKD 1-2 stages with type 2 DM.
About the Authors
V. M. Ibragimov
Dagestan State Medical University
Russian Federation
Russian Federation
Department of Faculty and Hospital Therapy №2
367015, Russia, Republic of Dagestan, Makhachkala, Lenin Avenue, 1
Associate Professor Vagif M. Ibragimov, MD, PhD
Phone: +7 (928) 941-13-84, 8 (872) 267-07-94
A. M. Aliskandiev
Dagestan State Medical University
Russian Federation
Russian Federation
Department of Faculty and Hospital Therapy №2, Head of the Department
367015, Russia, Republic of Dagestan, Makhachkala, Lenin Avenue, 1
Prof. Alaudin M. Aliskandiev, MD, PhD, DMedSci
Phone: +7 (960) 407-35-50
I. V. Sarvilina
Medical Center "Novomeditsina"
Russian Federation
Russian Federation
Сlinical diagnostic laboratory
344002, Russia, Rostov-on-Don, ul. Socialist, 74, office 1030
MD, PhD, DMedSci
Phone: 8(632)2003073, +79034364866
References
1. Дедов ИИ, Шестакова МВ, Майорова А.Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом, 8-й выпуск. Сахарный диабет 2017; 20(1S):1-112 [Dedov II, Shestakova MV, Mayorova AY. Algorithms of specialized medical care for patients with diabetes, 8th edition. Diabetes mellitus 2017; 20 (1S): 1-112]
2. Маслова ОВ, Сунцов ЮИ, Шестакова МВ и др. Распространенность диабетической нефропатии и хронической болезни почек при сахарном диабете в Российской Федерации. Клиническая нефрология 2010; (3):45-50 [Maslova OV, Suntsov YuI, Shestakova MV. The prevalence of diabetic nephropathy and chronic kidney disease in diabetes mellitus in the Russian Federation. Clinicheskaya nefrologiya 2010; (3): 45-50]
3. Нагайцева СС, Швецов МЮ, Шалягин ЮД и др. Факторы риска повышения альбуминурии как раннего маркера хронической болезни почек в разных возрастных группах. Нефрология 2013;17(4):58-62. https://doi.org/10.24884/1561-6274-2013-17-4-58- 62 [Nagaytseva SS, Shvetsov MY, Shalyagin YD et al. Assessment of albuminuria and chronic kidney disease risk factors in different gender groups. Nephrology (Saint-Petersburg). 2013;17(4):58-62. (In Russ.) https://doi.org/10.24884/1561-6274-2013-17-4-58-62]
4. Gall MA, Rossing P, Skøtt P et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin- dependent) diabetic patients. Diabetologia 1991; 34(9):655–661
5. Добронравов ВА, Галкина ОВ, Зубина ИМ, Смирнов АВ. Клинические факторы, ассоциированные с выявлением ранних стадий хронической болезни почек у больных сахарным диабетом 1 типа. Нефрология 2015;19(6):9-13 [Dobronravov VA, Galkina OV, Zubina IM, Smirnov AV. Clinical factors associated with the occurence of early stages of chronic kidney disease in patients with diabetes mellitus type 1. Nephrology (Saint- Petersburg). 2015;19(6):9-13. (In Russ.)]
6. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–2572 doi: 10.1056/NEJMoa0802987
7. Ekinci EI, Jerums G, Skene A et al. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. DiabetesCare 2013; 36(11):3620- 3626. Doi: 10.2337/dc12-2572
8. Hall JE, Henegar JR, Dwyer TM et al. Is obesity a major cause of chronic kidney disease? AdvRen Replace Ther 2004; 11(1):41-54. Doi: https://doi.org/10.1053/j.arrt.2003.10.007
9. Смирнов АВ, Добронравов ВА, Кисина АА и др. Клинические рекомендации по диагностике и лечению диабетической нефропатии. Нефрология 2015;19(1):67-77 [Smirnov AV, Dobronravov VA, Kisina AA et al. Clinical practice guideline for diagnostics and treatment of diabetic nephropathy. Nephrology (Saint-Petersburg). 2015;19(1):67-77 (In Russ.)]
10. Rask-Madsen C, King GL. Kidney complications: factors that protect the diabetic vasculature. NatMed 2010;16(1):40-41 [doi: 10.1038/nm0110-40]
11. Meeta Sharma, The RENAAL Study Investigation Clinical Diabetes 2002;20(1):19-20. Doi.org/10.2337/diaclin.20.1.19
12. Van Buren PN, Toto R. Hypertension in Diabetic Nephropathy: Epidemiology, Mechanisms, and Management. Advances in chronic kidney disease 2011;18(1):28-41. Doi:10.1053/j.ackd.2010.10.003.
13. Haller C. Hypoalbuminemia in Renal Failure. Pathogenesis and Therapeutic Considerations. Kidney Blood Press Res 2005; (28):307–310. Doi: 10.1159/000090185
14. McClellan W, Aronoff SL, Bolton WK, et al, The prevalence of anemia in patients with chronic kidney disease. Current Medical Research and Opinion 2004; 20(9): P.1501-1510. Doi: 10.1185/030079904X2763
15. Trimarchi H. Podocyturia: Potential applications and current limitations. World J Nephrol 2017;6(5): 221–228. Doi: 10.5527/wjn.v6.i5.221
16. Смирнов АВ, Добронравов ВА, Кисина АА и др. Диабетическая нефропатия. В: Шилов ЕМ, Смирнов АВ, Козловская НЛ, ред. Нефрология. Клинические рекомендации. ГЭОТАР-Медиа, М., 2016: 460-477 [Smirnov AV, Dobronravov VA, Kisina A.A. et al. Diabetic nephropathy In: Shilov EM, Smirnov A.V., Kozlovskaya NL, ed. Nephrology. Clinical recommendations. GEOTAR-Media, Moscow, 2016: 460-477]
17. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2017; 40 (1):S1- S135 [Doi. org/10.2337/dc17-in01]
18. Levey AS, Stevens LA, Schmid CH et al. A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med 2009; 150:604-612
Review
For citations:
Ibragimov V.M., Aliskandiev A.M., Sarvilina I.V. ABOUT THE ROLE OF THE PODOCIN PROTEIN IN DYSFUNCTION OF KIDNEYS IN PATIENTS WITH DIABETES MELLITUS TYPE 2. Nephrology (Saint-Petersburg). 2018;22(5):31-38. (In Russ.) https://doi.org/10.24884/1561-6274-2018-22-5-31-38
Views:
736
Email this article 